Nemaura Medical Inc. (NMRD)
OTCMKTS: NMRD · Delayed Price · USD
0.0650
+0.0050 (8.33%)
Apr 24, 2024, 3:39 PM EDT - Market closed
Company Description
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States.
It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients.
The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.
Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Nemaura Medical Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Dr. Dewan Fazlul Hoque Chowdhury Ph.D. |
Contact Details
Address: 57 West 57th Street Manhattan, New York 10019 United States | |
| Phone | 44-1509-222-912 |
| Website | nemauramedical.com |
Stock Details
| Ticker Symbol | NMRD |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001602078 |
| CUSIP Number | 640442208 |
| ISIN Number | US6404422080 |
| Employer ID | 46-5027260 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dewan Fazlul Hoque Chowdhury Ph.D. | Chairman, Interim Chief Financial Officer, Chief Executive Officer, President and Principal Financial and Accounting Officer |
| Dr. Arash Ghadar | Chief Operating Officer |
| Jay L. Warner | Head of U.S. Commercial Operations |
| Thomas Bendix Mortensen | Head of E.U. Commercial Operations and Marketing |
| Samantha Sanders | Global Head of Digital Programs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 8-K | Current Report |
| Apr 19, 2024 | PRE 14C | Filing |
| Apr 10, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 25-NSE | Filing |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 10-Q | Quarterly Report |
| Jan 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 17, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 3, 2024 | 8-K | Current Report |